1	BDNF, inflammatory and oxidative levels in treatment-
2	naïve ADHD children treated with methylphenidate: An
3	open cohort protocol.
4	
5	
6	Marina Silva de Lucca ^{1¶*} , Laira Lopes Tonon ^{2&} , Jordânia Alves Ferreira ^{2&} , Bárbara Silva
7	Cabral ^{2&} , Cleuberton Kenedy Oliveira Raimundo ^{2&} , Sílvia Almeida Cardoso ^{2¶} , Débora
8	Marques de Miranda ^{3¶}
9	
10	¹ Health Sciences Postgraduate Program, Faculty of Medicine, Federal University of
11	Minas Gerais, Belo Horizonte, Minas Gerais, Brazil.
12	² Department of Medicine and Nursing, Federal University of Viçosa, Minas Gerais, Brazil.
13	³ Department of Pediatrics, Faculty of Medicine, Federal University of Minas Gerais, Belo
14	Horizonte, Minas Gerais, Brazil.
15	* Corresponding author
16	E-mail: marinadelucca@ufv.br
17	
18	[¶] These authors contributed equally to this work.
19	^{&} These authors also contributed equally to this work
20	
21	
22	

23 Abstract

The attention-deficit hyperactivity disorder (ADHD) has a complex etiology, involving the interaction between biological, genetic, and environmental factors. The ADHD pathophysiology remains unknown even though there are hypotheses that inflammatory, hormonal, oxidative and neurotrophic factors are associated. This clinical trial aims to evaluate the contribution of brain derived neurotrophic factor (BDNF), inflammatory and oxidative levels before and after 12 and 24 weeks of methylphenidate use.

31

32 Methods

33 Patients will be screened upon their entry into Child and Adolescent Psychiatry 34 Teaching Outpatient Clinic of the Medical Course at the Federal University of Viçosa in 35 Minas Gerais, Brazil. One hundred and fifty ADHD treatment-naïve children of both sexes, between 6–14 years old, will be invited to participate, after the ADHD diagnosis by an 36 37 experienced psychiatrist and the child fulfilling the inclusion criteria. Children and their caregivers will answer questionnaires regarding mental health and the children will 38 undergo neuropsychological tests, physical, nutritional and activity assessment, in 39 40 addition to blood sampling at baseline, 12 and 24 weeks of methylphenidate use 41 respectively.

42

43 **Discussion**

This clinical trial intends to verify how the pharmacological treatment changes the plasma BDNF, inflammatory and oxidative levels in treatment-naïve Brazilian children

46 diagnosed for ADHD.

47

48 Trial Registration

49 Submitted for registration on Brazilian Registry of Clinical Trials (ReBEC).

50 Trial identifier: 13612

51 Registry name: Níveis de neurotrofina, perfil inflamatório e oxidativo em crianças com

52 TDAH tratadas com metilfenidato.

53

54 Administrative information – Spirit 2013 Checklist

55 Title {1}

56 BDNF, inflammatory and oxidative levels in treatment-naïve ADHD children treated with

57 methylphenidate: An open cohort protocol.

58

59 Trial registration

60 Registry {2a}

- 61 Submitted for registration on Brazilian Registry of Clinical Trials (ReBEC).
- 62 Trial identifier: 13612.
- 63 Registry name: Neurotrophin level, inflammatory and oxidative profile in ADHD children
- 64 treated with methylphenidate.

65

66 Data Set {2b}

- 67 The Universal Trial Number (UTN) is U1111-1285-2908.
- 68 Date recruitment began: 23/10/2020; Approximate date when recruitment will be
- 69 completed: 29/11/2022.

70

71 Protocol version {3}

- 72 First version.
- 73 Submitted for registration on Brazilian Registry of Clinical Trials (ReBEC).
- 74 Trial identifier: 13612.
- 75

76 Funding **{4**}

- 77 National Council for Scientific and Technological Development (CNPQ).
- 78 Research Support Foundation of the State of Minas Gerais (FAPEMIG APQ-01023/18)

79

80 Roles and Responsibilities {5}

81 Contributorship {5a}

- 82 Marina Silva de Lucca. Master in Physical Education and PhD student in Health Sciences,
- 83 Faculty of Medicine, UFMG.
- 84 Laira Lopes Tonon. Medicine student (UFV). Research volunteer member.
- 85 Bárbara Silva Cabral. Medicine student (UFV). Research volunteer member.

86 Jordânia Alves Ferreira. Medicine student (UFV). Scientific initiation scholarship

87 Cleuberton Kenedy Oliveira Raimundo. Medicine student (UFV). Research volunteer88 member.

- 89 Silvia Almeida Cardoso. Master and Doctor in Immunology (USP). Associate Professor
- 90 of Nursing and Medicine, Faculty of Medicine, UFV.
- 91 Débora Marques de Miranda. Master and Doctor in Biochemical and Molecular
- 92 Pharmacology (UFMG). Associate Professor of Pediatrics, Faculty of Medicine, UFMG.
- 93 ML is the Chief Investigator; she conceived the study, led the proposal and protocol
- 94 development. LLT, BSC, JAF and CKOR contributed to development of the proposal and

95 methodology. SC e DM contributed to study design and to development of the proposal

96 and methodology. All authors read and approved the final manuscript.

97

98 Sponsor contact information {5b}

99 Not applicable.

100

101 Sponsor and Funder {5c}

This funding source had no role in the design of this study and will not have any role during its execution, analyses, interpretation of the data, or decision to submit results.

105 Committees {5d}

Principal Investigator and Research Physician

- 107 Design and conduct the clinical appointments: Marina Silva de Lucca.
- 108 Preparation of protocol and revisions: Marina Silva de Lucca, Sílvia Almeida Cardoso,
- 109 and Débora Marques de Miranda.
- 110 Organizing steering committee meetings: Marina Silva de Lucca and Débora Marques de
- 111 Miranda.
- 112 Publication of study reports: Marina Silva de Lucca, Sílvia Almeida Cardoso, and Débora
- 113 Marques de Miranda.
- 114

115 Steering committee

- 116 The composition of the trial committee includes all authors.
- 117 Agreement of final protocol: Marina Silva de Lucca, Sílvia Almeida Cardoso, and Débora
- 118 Marques de Miranda.
- 119 All lead investigators will be steering committee members.
- 120 Recruitment of patients: Laira Lopes Tonon, Bárbara Silva Cabral and Jordânia Alves
- 121 Ferreira, Cleuberton Kenedy Oliveira Raimundo.
- 122 Reviewing progress of study and if necessary, agreeing changes to the protocol and/or
- 123 investigators brochure to facilitate the smooth running of the study: Marina Silva de Lucca
- 124 and Débora Marques de Miranda.
- 125

126 **Trial Management Committee (TMC)**

- 127 Study planning; Organization of steering committee meetings: Marina Silva de Lucca and
- 128 Débora Marques de Miranda.

- 129 Data verification: Marina Silva de Lucca.
- 130 Endpoint adjudication: Marina Silva de Lucca and Débora Marques de Miranda.

131

132 Data Management team

- 133 Data entry, data verification: Laira Lopes Tonon, Bárbara Silva Cabral, Jordânia Alves
- 134 Ferreira, Cleuberton Kenedy Oliveira Raimundo and Marina Silva de Lucca.

135

136 Lead Investigators

137 Marina Silva de Lucca, Sílvia Almeida Cardoso, and Débora Marques de Miranda.

138

- 139 Schedule of enrolment, interventions, and
- 140 assessments

141

142 Introduction

143

144 Background and rationale {6a}

Attention deficit hyperactivity disorder (ADHD) is a neurodevelopmental disorder characterized by symptoms of inattention, hyperactivity, and impulsivity that appear in childhood and usually persist into adulthood, causing some degree of dysfunction in daily

activities [1,2,3]. The heterogeneous clinical presentations of ADHD are a hallmark of this
disorder [4] important negative outcomes are reported, both in terms of morbidity and
mortality [3].

ADHD has a complex etiology, involving the interaction between genetic, biological and environmental factors. However, its pathophysiology remains unknown [5]. There are hypotheses that inflammatory, oxidative, hormonal, and neurotrophic factors are associated, and they have mutual interactions. [3,6].

155 Different ADHD risk factors, such as prematurity, paternal smoking, exposure to 156 pesticides and lead may be associated with common pathophysiological pathways, such 157 as inflammation, oxidative stress, and neurotrophic factors. Likewise, intrauterine pro-158 inflammatory factors during the gestational period may be associated with restricted 159 intrauterine growth, miscarriage, premature birth, placenta abruption, neurological 160 damage, some of which are risk factors for ADHD [7,8,9, 10, 11, 12]. Neuroinflammation 161 in physiological and pathological conditions may activate microglia, astrocytes, 162 oligodendrocytes, and ependymal cells. In addition, it may increase proteases, glutamate, 163 reactive oxygen species, nitric oxide, chemokines, toxic cytokines, prostaglandins, and 164 may induces infiltration of T and B neutrophils, monocytes/ macrophages and dendritic 165 cells. When activated, these cells release pro-inflammatory cytokines that increase 166 neuroinflammation [13]. Some cytokines are elevated in ADHD, some of which are related 167 to the severity of symptoms [13, 14, 15]. A systematic review on the level of cytokines in 168 peripheral blood showed increased levels of cytokines-interleukin-6 (IL-6) in patients with 169 ADHD, especially in those younger than eighteen years and not on medication, when 170 compared to a healthy control group [13, 16]. However, another systematic review found

171 no difference in IL-6 levels when comparing children with and without ADHD [17]. 172 Furthermore, patients with ADHD, especially in those younger than eighteen years and 173 not on medication, had lower levels of tumor necrosis factor-alpha human (TNF-alpha) 174 compared to healthy controls [16, 17]. The results regarding cytokines-interleukin-10 (IL-175 10) were contradictory and may be increased or unchanged in children with ADHD 176 compared to children without the pathology [13, 16, 17]. ADHD treated patients seem to 177 have a decrease in interferon gamma (IFN-gamma) and interleukin-13 (IL-13) levels, 178 compared to those naïve to treatment [13].

179 Therefore, neuroinflammation could alter the blood-brain barrier, neurotransmitter 180 metabolism, increase oxidative stress, and neurodegeneration [14, 15]. Animals and 181 humans with ADHD show, in different brain structures, an increase in reactive oxygen 182 species without an adequate antioxidant response, resulting in an increase in oxidative 183 stress. This negative imbalance in ADHD may be explained in the central nervous system 184 due to the large consumption of oxygen by neurons associated with an antioxidant 185 defense system of modest action and a constitution rich in lipids. As a result, the brain 186 has difficulty regulating excess reactive oxygen species, making it more susceptible to 187 damage [15, 18, 19, 20, 21, 22]. Therefore, there is evidence of increased oxidative stress 188 in ADHD patients [19, 20, 21 22, 23, 24].

ADHD may be associated with a decrease in ascorbate, catalase, albumin and bilirubin and an increase in uric acid. So, it may contribute to oxidative stress increase [25]. On the other hand, treatment with methylphenidate seems to increase catalase levels. Other study demonstrated that the activity of superoxide dismutase (SOD), an important antioxidant defense enzyme, is lower in patients with ADHD [25].

194 Increased oxidative stress may be associated with reduced levels of BDNF, as well as reduced oxidative stress with increased BDNF [26]. Therefore, changes in the BDNF 195 196 expression at critical moments during development may promote a cascade of events 197 interfering with the brain maturation of some regions, being a substrate for altered 198 response to stress in adulthood and development of neuropsychiatric disorders [26]. 199 Another evidence of intense oxidative stress is the modulation of telomere size and 200 shortening during life [27] and telomere shortening is present in ADHD children [28]. So, 201 telomere length may be a potential biomarker of the ADHD symptoms burden in families 202 affected by this neurodevelopmental disorder [29].

Studies with rats have been trying to observe the results of chronic use of methylphenidate in brain cells [30, 31, 32]. Chronic use of methylphenidate in healthy rats caused oxidative damage in the brain of young rats [30]. Furthermore, the chronic use of methylphenidate by adult rats induced oxidative stress and inflammation in the hippocampus, causing cellular damage in this area [31]. Increased oxidative stress was also observed in spontaneously hypertensive adult rats (animal version of ADHD) [32].

In ADHD children and adolescents' study, low levels of nitric oxide were found in baseline, which did not change significantly with the use of methylphenidate over ten weeks [33]. Guney et al. (2015) [33] found that methylphenidate may reduce oxidant levels and increase antioxidant levels in children and adolescents.

213 Studies have evaluated BDNF levels in individuals with ADHD, comparing them 214 with typical children [17, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51] 215 and after stimulant treatment [40, 45, 50, 51, 52], with divergent results.

Due to the controversial studies and the importance of treating ADHD, this protocol study aims to explain the methodology that will evaluate BDNF, inflammatory and oxidative levels, their associated factors in ADHD treated children for 6 months with methylphenidate.

220

221 Choice of comparators {6b}

BDNF, inflammatory markers and oxidative stress levels of the ADHD children will be compared before and after methylphenidate use. Therefore, the same group of children will be compared in three different times: before starting methylphenidate and after 12 and 24 weeks of methylphenidate use. All patients will be in follow-up at the child and adolescent psychiatry outpatient clinic, receiving pharmacological treatment for ADHD. Local health system provides free methylphenidate (generic medication) in the presentation of 10mg, immediate-release tablets.

229 Control groups (ADHD children without methylphenidate use) will not be 230 possible, because it would be unethical to deprive them of effective treatment, capable of 231 reducing not only morbidity, but also mortality.

232

233 Objectives {7}

The objectives of this open cohort clinical trial will be:

Evaluate the BDNF, inflammatory and oxidative levels before and after 12 and 24
 weeks of methylphenidate use in treatment-naïve ADHD children.

237	2.	Investigate if there is a moderating effect of the sociodemographic data, ADHD
238		presentation, comorbidity presence, caregiver psychopathology, parenting styles,
239		emotional regulation level on BDNF, cytokines and oxidative stress level, telomere
240		length, and other variables from the survey instruments detailed throughout this
241		protocol.
242		

243 Trial Design {8}

244 This trial is designed as an open cohort, single center, with convenience sample.

245

246 Methods: Participants, Interventions, Outcomes

247 Study setting {9}

All subjects will be invited to the child psychiatry teaching outpatient clinic at the Federal University of Viçosa (UFV), in the state of Minas Gerais, Brazil.

250

251 Eligibility criteria {10}

252 **Participants inclusion criteria: {10}**

Treatment-naïve ADHD children, of both sex in outpatient treatment; age between complete 6 and incomplete 15 years old. Children must have criteria for ADHD diagnosis according to the DSM-5 and must not have chronic diseases or use of any other medications that may interfere with the immune system or BDNF. Children who need iron or vitamin replacement may be included. The following comorbidities may be included:

258 oppositional defiant disorder (ODD), tic disorder, enuresis, encopresis, skin picking 259 disorder. Autism spectrum disorder (ASD) level 1, Classification of Diseases and Related 260 Health Problems (ICD) 10 F84.5, could be included if the diagnosis occurs during the 261 study. All parents must sign the free and informed consent form, just like children should 262 also sign the assent form. The terms will be delivered during the initial assessment of the 263 participants, if they wish to participate voluntarily in the research.

264

265 **Participants exclusion criteria: {10}**

266 Families and children that refusal to participate in the research or refusal to use 267 stimulant medications; presence of autoimmune, neurodegenerative diseases, and immunodeficiencies; intellectual disability, severe clinical or psychiatric comorbidities, 268 269 except autism spectrum disorder level 1 (ICD 10 F84.5), ODD, tics, trichotillomania, skin 270 picking disorder, enuresis, and encopresis; previous or current use of stimulants or other 271 psychiatry medications; current use of medications for chronic diseases or that interfere 272 in immune system or BDNF levels (antidepressants for example); girls who have 273 menstruated; stimulant contraindication use.

274

275 **Participant timeline: {13, 14, 15, 18}**

Participants will be included from October 2020 to November 2022, targeting a
sample size of 150 children, based on sample calculation with analysis power between
80% and 95% of accuracy. This sample calculation was based on an article of Akay et
al., 2017 [37].

They will be forwarded by physicians, schools and psychologists from the city and health region. To reach the sample number, the health units, as well as the municipal education department were communicated about the research and how the children could be referred for screening. There was also publicity on the local radio and the website of the Federal University of Viçosa.

285 Children who are eligible for the study will be categorized by ADHD presentation, 286 disorder severity, with or without Oppositional Defiant Disorder (ODD), with or without 287 autism spectrum disorder (ASD), at any emotional dysregulation level. Their caregivers 288 will be sorted by parenting style.

289 Overall, each participant will make 8 to 10 visits during the study period.

290 The research procedure for participants at each visit are described in Fig. 2.

The initial assessment includes the semi-structured interview Kiddie-Schedule for Affective Disorders and Schizophrenia – Present and Lifetime Version (K-Sads-PL 2013) [53].

294 To assess the severity of ADHD symptoms, the SNAP-IV scale, Swanson, Nolan 295 e Pelham version [54], and the Assessment Scale of Childhood and Adolescent 296 Behaviors in ADHD in a Family Environment (ETDAH-parents) [55] and ADHD Self-297 Assessment Scale-Version for Children and Adolescents (ETDAH-Criad) [56] were 298 answered by parents and children. The SNAP-IV scale has 26 items, which also 299 investigates symptoms of a common comorbidity that is Defiant and Oppositional 300 Disorder. [54]. The ETDAH scale has one version for parents and another for the children. 301 [55,56]. The parent subscale has four subscales that investigates symptoms of 302 inattention, hyperactivity/impulsivity, emotional regulation, and adaptive behavior. The

303 children subscale has 2 subscales that investigates inattention and 304 hyperactivity/impulsivity symptoms.

The diagnosis will be confirmed by a interview done by a Child and Adolescent Psychiatrist. Sociodemographic data was obtained from the Brazil Economic Ranking Criterion and "Background information" part of the K-Sads-PL instrument (K-Sads-PL 2013) [53, 57, 58]. A standard record for the clinical history was constructed with data on pregnancy, childbirth, neuropsychomotor development, and the child's previous and family history.

311 For the care of children at the outpatient clinic, an anamnesis model was built. 312 This anamnesis also includes a habitual physical activity questionnaire [59], Brazilian food 313 safety scale [60], SISVAN food consumption markers questionnaire [61], food frequency 314 [62. 63]. bullying questionnaire (Kidscape) questionnaire [64], measurement questionnaire adherence to treatment [65], CRAFFT/CESARE instrument (Car; Relax; 315 316 Alone; Forget; Family/Friends; Trouble acronym) [66].

317 Situations of violence and/or health identified during the research will be duly 318 forwarded to the necessary assistance network, such as justice, other medical specialties, 319 social services, and others. The caregiver is screened for symptoms of depression, 320 anxiety, ADHD, and alcohol use [67, 68, 69, 70]. In case of positive screening, evaluation 321 by an adult psychiatrist will be offered.

322

323 Interventions {11a, 18}

324 Screening visits

325		Medical students trained by an experienced child and adolescent psychiatrist
326	and u	nder her supervision, will apply in the first assessment (between one and three
327	visits)	: Fig. 1. Schedule of enrolment, interventions, and assessments.
328	#	Multimodal Treatment Assessment Study – Swanson, Nolan e Pelham (MTA-
329		SNAP-IV) scale, that evaluates symptoms of attention deficit/hyperactivity disorder
330		and oppositional defiant disorder in children and adolescents [54]
331	#	Kiddie Schedule for Affective Disorders and Schizophrenia for School Aged
332		Children – Lifetime Version (K-Sads-PL 2013) [53]
333	#	Sociodemographic questionnaire, including the Brazil Economic Ranking Criterion
334		and the background information of the K-Sads-PL 2013 [53,57,58]
335	#	ADHD Behavior Assessment Scale – Parents Version (ETDAH-parents) [55]
336	#	Bullying questionnaire [64]
337	#	Physical activity questionnaire [59]
338	#	SISVAN food consumption markers [61]
339	#	Brazilian Food Security Scale (EBIA) [60]
340	#	Scale of Sleep disorders in children [72]
341	#	Behavior Inventory for Children and Adolescents (CABI) [73]
342	#	Parenting Styles and Dimensions Questionnaire – Short Version (PSDQ) [74]
343	#	Epidemiological Studies Center Depression Scale (CES-D) [67]
344	#	State-Trait Anxiety Inventory (IDATE) [68]
345	#	Adult Self-Report Scale (ASRS-18) [69]
346	#	Alcohol Use disorders identification test (AUDIT) [70]
347	#	Standardized psychiatric clinic interview with standard record.

348	# Physical examination.								
349									
350	Psychology students, under supervision of an experienced psychologist in								
351	neuropsychology will apply:								
352	# Scale for screening drug use CRAFFT/CESARE [66]								
353	# Social Skills Test for Children and Adolescents in School Situation (THAS-C) [75]								
354	# ADHD Self-Assessment Scale – Version for Children and Adolescents (ETDAH-								
355	CriAd) [56]								
356	# Standardized and validated psychological tests for the Brazilian population.								
357	 Non-Verbal test of Children's Reasoning (TNVRI) [76] 								
358	Battery for Attention Assessment (BPA) [77, 78]								
359	• Five digits teste (FDT) [79]								
360	• Brief Child Neuropsychological Assessment Instrument (NEUPSILIN-inf)								
361	[80]								
362									
363	Nutrition's student under supervision of an experienced nutritionist will apply:								
364	# 24-hour food recall [81, 82]								
365									

366 Assessment points {11a, 18a}

The assessment points occur in three timepoints: baseline (before methylphenidate initial use) and after 12 and 24 weeks of methylphenidate use. Fig 1 and 2.

370 In the first assessment point the blood sample is collected, the family receives 371 psychoeducation about the disorder and its treatment, and the methylphenidate is started.

372 In the second and third assessment points, all instruments will be applied in 373 screening are reapplied, except K-Sads-PL, sociodemographic questionnaire, 374 standardized psychiatric clinic interview with standard record and NEUPSILIN-inf. In 375 these two timepoints, we will use standardized follow-up anamnesis. Participants will also 376 be clinically evaluated to verify the effect of the treatment (the Clinical Global Impressions 377 (CGI) scale) [83, 84, 85], dose adjustment, the presence of adverse effects, adherence 378 to treatment, clarification of doubts regarding the research, the disorder, and the 379 treatment and reinforce the guidelines regarding the next steps of the study.

380

Follow-up visits {11a, 18a}

Participants will also be clinically evaluated at 4, 8 and 18 weeks to verify the effect of the treatment, dose adjustment, the presence of adverse effects, adherence to treatment, clarification of doubts regarding the research, the disorder, the treatment and reinforce the guidelines regarding the next steps of the study.

386 The number of visits could vary, depending on the patient's individual needs.

387 Pharmacotherapy {11b}

388 Pharmacotherapy will be conducted by experienced child and adolescent 389 psychiatry with primary responsibility for childcare.

390 Pharmacotherapy starts with a first-line stimulant medication methylphenidate.
391 [86]. The initial dose will be prescribed as follows: 5mg in the morning and after lunch in

the first week, with adjustment to 10mg at the same time until the next evaluation at 4
weeks. From that moment on, the dose will be titrated to optimize the desired therapeutic
effect and minimize undesirable adverse effects. The average dose will be 1 mg/kg/day.
If the child does not tolerate the methylphenidate [87, 88] or does not respond to
medication, lisdexamfetamine will be offered. [88] Other formulations may be used such
as methylphenidate hydrochloride extended-release capsules or OROS methylphenidate
if necessary. In these cases, equivalent doses will be prescribed.

399

400 Blood sample {11a}

A trained nursing professional will collect three samples of venous blood from each patient/volunteer: before medication treatment, 12 and 24 weeks after starting treatment. Blood samples will be kept at a suitable temperature [89] until they are sent to the Biochemistry laboratory of the Department of Biochemistry (UFV). The BDNF [90] and the cytokines levels [91, 92, 93, 94] will be evaluated in blood plasma and the oxidative stress [95,96] level will be evaluated in serum. Telomeres measurements will be made by DNA extraction [27, 28, 29].

408

Adherence to intervention protocols {11c, 18b}

To improve adherence to medical visits and research evaluations, nursing technique will confirm the consultation by telephone (calls or WhatsApp messages) the day before. In case of participant absence, contact by phone will be made to offer appointment rescheduling.

The assessment methylphenidate adherence will be by pill count and the Treatment Adherence Measure (MAT) questionnaire [65] in all scheduled visits [97].

417 Modifications {11b}

The participant will be excluded from the survey if he does not attend the assessment points (blood collection times). If the patient reports the impossibility of attending the assessment visit and is available to reschedule it within a maximum of 15 days, the patient can proceed with the intervention. The patient may miss the visits number 4, 8, 18 and proceed with the intervention, if the regular use of medication continues.

The child will be excluded in case of not tolerating the medication, family withdraws from participation, diagnosis change during follow-up.

The pharmacological intervention may have adverse effects and the child will receive all the necessary and standard care following strictly the clinical protocol. Most adverse effects are usually mild and occur early in treatment [87]. They will be informed and medication will be adjusted accordingly the need.

Participants whose diagnosis on screening differs from the diagnosis of thepsychiatry team will be excluded from the study.

432

433 **Concomitant care {11d}**

434 The treatment can also include speech therapy and occupational therapy if there 435 is a clinical indication. The psych treatment was not available.

436

437 Outcomes {12}

438 **Primary outcomes:**

439 The BDNF levels [37], cytokines and level of oxidative stress (oxidative and 440 antioxidant substances) after treatment with methylphenidate.

441

442 Secondary outcomes:

443 Deficit/Hyperactivity Behavioral symptoms of Attention Disorder and/or Oppositional Defiant Disorder, emotional regulation level determined by the Multimodal 444 445 Treatment Assessment Study - Swanson, Nolan e Pelham (MTA-SNAP-IV) scale, which assesses symptoms of attention deficit/hyperactivity disorder and Oppositional Defiant 446 447 Disorder in children and adolescents, and ETDAH - parents, which assesses emotional 448 regulation.

449 Cardiovascular parameters on physical examination, as well as body mass index450 will be recorded.

451

452 **Retention {18b}**

The intervention has the potential to bring great benefits to the child and whole family. The stimulant treatment in ADHD children is associated with reduced morbidity and mortality.

WhatsApp contact will be possible for participants to clarify their doubts, reschedule the appointment, as well as be reminded of the appointments during the period in which they participate in the study.

459 Moreover, a report containing the child's neuropsychological assessment will be 460 given to the parents. In addition, all children will be under medical supervision at the 461 outpatient clinic, even after the end of the study (UFV).

462 Post-intervention measures will not be necessary after the twenty-fourth week.
463 The analysis will be performed with the information obtained up to the time of dropping
464 out in case of child drops out of the study.

465

466 Data Management {19}

467 A part of the data will be entered electronically and registered in REDCap 468 database. A random sampling checking will be done to quality control.

469 Participant research files are attached to their medical records, so they will be470 kept for 20 years after the last registration.

471

472 Statistical Methods {20}

473 **Outcomes {20a}**

The main analysis strategies will involve group comparison from the three timepoints and trajectory of symptoms and measures across time. Generalized Estimating Equations (GEE) analyses may be done with risk factors and potential

477 moderators such social deprivation, parental styles, and oppositional symptoms to478 understand the relationship.

479

480 Additional analyses {20b}

481 The main additional analyses strategies will involve descriptive data to 482 characterize the studied sample and to observe the correlations between features.

483

484 Analysis Population and Missing Data {20c}

Individuals that will not fill the information of the primary outcomes will have the
other data analyzed: sociodemographic profile, BDNF dosages, cytokines, and oxidative
stress at baseline to understand potential populational bias.

488 Missing data will be handled as necessary for the chosen tests, for GEE for 489 example we will include only individuals with the complete data set for primary outcomes.

490 We will try to retrieve all information by WhatsApp contact.

491

- 493 **Methods: Monitoring**
- 494 Data Monitoring {21}
- 495 Formal Committee {21a}

Diagnosis data was done by thirteen years experienced child psychiatry and there is a team on UFMG to discuss any doubt prof. DMM and AASJ. They also have 15 years of experience in the field.

499

500 Interim Analyses {21b}

501 Individuals that will not fill the information of the primary outcomes will have the 502 other data analyzed: sociodemographic profile, BDNF dosages, cytokines, and oxidative 503 stress at baseline.

504 Socioeconomic data will be analyzed to evaluate any potential of sampling bias.

505 The clinical psychiatric assessment will be done by an experienced child and 506 adolescent psychiatry, and any diagnosis divergence will be informed. Adherence will be 507 considered poor if the child takes less than 2/3 of prescribed doses of methylphenidate.

508

509 Harms {22}

- 510 Adverse events during the trial will be registered in the child's medical record and
- 511 communicated to the relevant governmental agencies if necessary.
- Assistance in case of adverse events will be guaranteed to the child via the publichealth system.

514

515 Auditing **{23}**

516 All data will be available to audit if necessary. The diagnosis divergence will be 517 evaluated and informed as soon as it is verified.

518

519 Ethics and Dissemination

520 Research Ethics Approval {24}

521 Approved by the Research Ethics Committee of the Federal University of Minas 522 Gerais. Number: 4.364.744. CAAE: 82870117.0.3001.5149. Written, informed consent 523 to participate will be obtained from all parents, as well as informed assent from the 524 children.

525

526 Protocol Amendments {25}

527 Any modifications to the protocol which may impact on the conduct of the study, 528 potential benefit of the patient or may affect patient safety, will lead to a formal 529 amendment to the protocol with REBEC, the ethics committee and clinical trial publication 530 journal.

531

532 Consent or Assent {26}

533 Consent or Assent {26a}

All parents must sign the free and informed consent form, as well as the children the assent form. The terms will be delivered at the end of the child's screening if the child is considered eligible to be included in the study and they wish to participate voluntarily in the research.

539 Ancillary Studies {26b}

540 Not Applicable

541

542 Confidentiality {27}

- 543 All study-related information will be stored securely at the child's medical record.
- 544 All local databases will be secured with password-protected access systems.

545

546 Declaration of Interests {28}

547 The author(s) declare(s) that they have no competing interests.

548

549 Access to Data {29}

550 All researchers will have access to the final trial dataset without any contractual 551 limitations.

552

553 Ancillary and Post-trial Care {30}

554 The children will continue clinical treatment at the child psychiatry outpatient 555 clinic for as long as the family wishes, or they will be discharged or reach the age of 18, 556 when they will be referred to adult services.

557

558 Dissemination Policy {31}

559 Trial Results {31a}

560 All research data and personal information will be under responsibility of the 561 researchers to protect confidentiality before, during and after the trial. All parents or 562 guardians' results will be communicated at the end and regarding the trial results.

563 Trial results will be published at REBEC, regardless of the magnitude or direction 564 of effect. The results will also be reported in an original article and submitted for a relevant 565 journal.

566

567 Authorship {31b}

568 ML is the Chief Investigator; she conceived the study, led the proposal and protocol 569 development. L, B and J contributed to development of the proposal and methodology. 570 SC e DMM contributed to study design and to development of the proposal and 571 methodology. All authors will read and approve the final manuscript.

572

573 Reproducible Research {31c}

574 The anonymous data information might be available under request and reasonable 575 demand.

576

577 **Discussion**

578 Inflammatory, neurotrophic, and oxidative parameters have been associated with 579 the pathophysiology of ADHD. Limitations in the studies varies from small and

heterogeneous samples of participants [12], lack of control for variables that may interfere with the results, such as diet, body mass index, short follow-up time, and level of physical activity, are some of these limitations. Moreover, the results are contradictory [98]. Here we propose a protocol trying to make clear clinical and biomarkers in response to medication in a cohort well characterized in a prospective follow up.

585 Many studies were cross-sectional and retrospective, which allows inferring only 586 an association between inflammation and the disorder and not a causal relationship of 587 pathogenesis [98]. Longitudinal studies are necessary to better establish the possible 588 relationship between ADHD, inflammation, neurotrophic, and oxidative stress [16]. Other 589 important factors to be considered are comorbid mental disorders and potential 590 confounding factors, in addition to being important to observe possible changes in the 591 inflammatory profile after interventions [16].

This trial protocol methodology will follow the participants by 24 weeks, increasing the chance of evaluating the influence of the chronic use of methylphenidate on inflammatory, neurotrophic, and oxidative factors. In addition, there will be evaluation of the child's diet and physical activity through the food recall and the usual physical activity questionnaire, respectively. To reduce hormonal influences of puberty, we will exclude girls who had menarche and limited the age of both sexes to 14 years.

598 The results may provide information about the pathophysiology of ADHD, being able 599 to collaborate in the identification of biomarkers of the disorder and response to treatment 600 with methylphenidate.

601

602

603 Acknowledgements

604 Acknowledgment to the entire Specialized Health Care team (UAES/UFV), Biochemistry and Medicine laboratory (UFV) team, Molecular Medicine laboratory 605 606 (UFMG) team, scientific initiation students (UFV), psychology students (volunteer 607 member/Univiçosa), nutrition professor and student (UFV), the neuropsychologist 608 Roselaine da Cunha Barros (volunteer member), and the nursing techniques Arieta de 609 Jesus Felisberto Oliveira (UFV) e Ana Cristine Pepe Parabocz (UFV). 610 **Appendices** 611 612 Appendix 1. Informed consent materials {32} 613 614 Appendix 2. Consent and Assent forms {32} 615 **Appendix 3. Biorepository constitution {32}** 616 617 **Biological specimens {33}** 618 619 Collection and analysis of biological samples will follow standard protocols for 620 these procedures in accordance with health surveillance recommendations. 621 Biorepository term was signed and contains the norms of storage and use in 622 auxiliary and future studies. (Appendix 3)

623

624 **References**

- Biederman J, Faraone S. Attention-deficit Hyperactivity Disorder. Lancet. 2005;
 (9481):237–248.
- 627 2. Edition F. Diagnostic and Statistical Manual of Mental Disorders. American
 628 Psychiatric Association. 2013; 21.
- 3. Sharma A, Couture J. A Review of the Pathophysiology, Etiology, and Treatment
 of Attention-Deficit Hyperactivity Disorder (ADHD). Annals of Pharmacotherapy.
 2013 Nov;48(2):209–25.
- 4. Drechsler R, Brem S, Brandeis D, Grünblatt E, Berger G, Walitza S. ADHD:
 Current Concepts and Treatments in Children and Adolescents. Neuropediatrics
 [Internet]. 2020 Oct 1;51(5):315–35.
- 5. Núñez-Jaramillo L, Herrera-Solís A, Herrera-Morales WV. ADHD: Reviewing the
 Causes and Evaluating Solutions. Journal of Personalized Medicine. 2021 Mar
 1;11(3):166.
- 6. Dursun S, Demirci E, Kilic E, Ozmen S. A Different View on the Etiopathogenesis
 of Attention-deficit Hyperactivity Disorder from an Inflammation Perspective.
 Clinical Psychopharmacology and Neuroscience. 2021 Feb 28;19(1):145–54.
- 7. Larson K, Russ SA, Kahn RS, Halfon N. Patterns of Comorbidity, Functioning, and
 Service Use for US Children With ADHD, 2007. Pediatrics [Internet]. 2011 Mar
 1;127(3):462–70.
- 8. Heyer DB, Meredith RM. Environmental toxicology: Sensitive periods of
 development and neurodevelopmental disorders. NeuroToxicology. 2017 Jan;
 58:23–41.

- 9. Sogard AS, Mickleborough TD. The therapeutic potential of exercise and caffeine
 on attention-deficit/hyperactivity disorder in athletes. Frontiers in Neuroscience.
 2022 Aug 12;16.
- 10. Lopresti AL. Oxidative and nitrosative stress in ADHD: possible causes and the
 potential of antioxidant-targeted therapies. ADHD Attention Deficit and
 Hyperactivity Disorders. 2015 Apr 19;7(4):237–47.
- 11. Abdollahi M, Ranjbar A, Shadnia S, Nikfar S, Rezaie A. Pesticides, and oxidative
 stress: a review. Medical Science Monitor: International Medical Journal of
 Experimental and Clinical Research [Internet]. 2004 Jun 1;10(6):RA141-147.
- 12. Dunn GA, Nigg JT, Sullivan EL. Neuroinflammation as a risk factor for attention
 deficit hyperactivity disorder. Pharmacology Biochemistry and Behavior [Internet].
 2019 Jul; 182:22–34.
- Anand D, Colpo GD, Zeni G, Zeni CP, Teixeira AL. Attention Deficit/Hyperactivity Disorder and Inflammation: What Does Current Knowledge
 Tell Us? A Systematic Review. Front Psychiatry. 2017; 8: 228.
- 14. Noakes PS, Thomas R, Lane C, Mori TA, Barden AE, Devadason SG, et al.
 Association of maternal smoking with increased infant oxidative stress at 3 months
- of age. Thorax [Internet]. 2007 Aug 1 [cited 2021 Aug 1];62(8):714–7.
- 665 15. Alvarez-Arellano L, González-García N, Salazar-García M, Corona JC. Antioxidants as
- a Potential Target against Inflammation and Oxidative Stress in AttentionDeficit/Hyperactivity Disorder. Antioxidants. 2020 Feb 21;9(2):176.
- 16. Misiak B, Wójta-Kempa M, Samochowiec J, Schiweck C, Aichholzer M, Reif A,
 Samochowiec A, Stańczykiewicz B. Peripheral blood inflammatory markers in

670	patients with attention deficit/hyperactivity disorder (ADHD): A systematic review
671	and meta-analysis. Progress in Neuro-Psychopharmacology Biological Psychiatry.
672	2022: 118.

- 17. Chang JP, Mondelli V, Satyanarayanan SK, Chiang YJ, Chen HT, Su KP, Pariante
- 674 CM. Cortisol, inflammatory biomarkers and neurotrophins in children and
 675 adolescents with attention deficit hyperactivity disorder (ADHD) in Taiwan. Brain,
 676 behavior, and immunity. 2020; 88:105–113.
- 18. Youdim MBH, Edmondson D, Tipton KF. The therapeutic potential of monoamine
 oxidase inhibitors. Nature Reviews Neuroscience [Internet]. 2006 Apr 1;7(4):295–
 309.
- Leffa DT, Bellaver B, de Oliveira C, de Macedo IC, de Freitas JS, Grevet
 EH, Caumo W, Rohde LA, Quincozes-Santos A, Torres ILS. Increased Oxidative
 Parameters and Decreased Cytokine Levels in an Animal Model of
 AttentionDeficit/Hyperactivity Disorder. Neurochemical research, 2017; 42(11):
 30843092. DOI: 10.1007/s11064-017-2341-6.
- 20. Annelies V, Harry R, Annelies B, Tess DB, Nina H. Evaluation of Biomarkers of
 Oxidative Stress in Attention-Deficit/ Hyperactivity Disorder (ADHD). Journal of
 Molecular Biomarkers & Diagnosis. 2018;09(03).
- 21. Joseph N, Zhang-James Y, Perl A, Faraone SV. Oxidative Stress and ADHD.
 Journal of Attention Disorders. 2013 Nov 14;19(11):915–24.
- 690 22. Sezen H, Kandemir H, Savik E, Basmacı Kandemir S, Kilicaslan F, Bilinc H, et al.
 691 Increased oxidative stress in children with attention deficit hyperactivity disorder.
- 692 Redox Report. 2016 Feb 18;21(6):248–53.

- 693 23. Faraone SV, Asherson P, Banaschewski T, Biederman J, Buitelaar JK, Ramos-
- 694 Quiroga JA, et al. Attention-deficit/hyperactivity disorder. Nature Reviews Disease 695 Primers [Internet]. 2015 Aug 6; 1:15020.
- 696 24. Wynchank D, Bijlenga D, Beekman AT, Kooij JJS, Penninx BW. Adult Attention-
- 697 Deficit/Hyperactivity Disorder (ADHD) and Insomnia: an Update of the Literature.
- 698 Current Psychiatry Reports. 2017 Oct 30;19(12).
- **699 25.** Lu Z, Pu C, Zhang Y, Sun Y, Liao Y, Kang Z, et al. Oxidative Stress and Psychiatric
- 700 Disorders: Evidence from the Bidirectional Mendelian Randomization Study.701 Antioxidants. 2022; 11:1386.
- 702 26. Asghari A, Hosseini M, Beheshti F, Shafei MN, Mehri S. Inducible nitric oxide inhibitor
 703 aminoguanidine, ameliorated oxidative stress, interleukin-6 concentration, and
 704 improved brain-derived neurotrophic factor in the brain tissues of neonates born from
 705 titanium dioxide nanoparticles exposed rats. The Journal of Maternal-Fetal &
 706 Neonatal Medicine. 2018 Jun 17;32(23):3962–73.
- 27. Drury SS, Theall K, Gleason MM, Smyke AT, De Vivo I, Wong JY et al. Telomere
 length and early severe social deprivation: linking early adversity and cellular
 aging. Molecular Psychiatry. 2012; 17(7): 719-27.
- 28. Pham C, Vryer R, O'Hely M, Mansell T, Burgner D, Collier F et al., On Behalf of
 The Barwon Infant Study Investigator Group. Shortened Infant Telomere Length Is
 Associated with Attention Deficit/Hyperactivity Disorder Symptoms in Children at
 Age Two Years: A Birth Cohort Study. International Journal of Molecular Sciences.
 2022; 23(9): 4601.

29. Costa DS, Rosa DV, Barros AG, Romano-Silva MA, Malloy-Diniz LF, Mattos P et
al. Telomere length is highly inherited and associated with hyperactivity-impulsivity
in children with attention deficit/hyperactivity disorder. Frontiers in Molecular
Neuroscience. 2015; 8: 28.

- 30. Martins M, Reinke A, Petronilho F, Gomes K, Dal-Pizzol F, Quevedo J.
 Methylphenidate treatment induces oxidative stress in young rat brain. Brain
 research. 2006; 1078: 189-197.
- 31. Motaghinejad M, Montevalian M, Shabab B. Effects of chronic treatment with
 methylphenidate on oxidative stress and inflammation in hippocampus of adult
 rats. Neuroscience letters. 2016; 619: 106-113.
- 32. Comim CM, Gomes KM, Réus GZ, Petronilho F, Ferreira GK, Streck EL,
 Dal-Pizzol F, Quevedo J. Methylphenidate treatment causes oxidative stress and
 alters energetic metabolism in an animal model of attention-deficit hyperactivity
 disorder. Acta Neuropsychiatrica. Cambridge University Press. 2014; 26(2): 96103.
- 33. Doneray E, Yazici KU, Yazici IP, Ustundag B. Altered Arginine/Nitric Oxide
 Pathway in Children Diagnosed Attention Deficit Hyperactivity Disorder, and the
 Effect of 10 Weeks Methylphenidate Treatment. Clinical Psychopharmacology and
 Neuroscience. 2022; 20(2): 350-363.
- 34. Guney E, Cetin FH, Alisik M, Tunca H, Tas Torun Y, Iseri E, et al. Attention Deficit
 Hyperactivity Disorder and oxidative stress: A short term follow up study.
 Psychiatry Research. 2015 Sep;229(1-2):310–7.

- 35. Shim SH, Hwangbo Y, Kwon YJ, Jeong HY, Lee BH, Lee HJ, Kim YK. Increased
 levels of plasma brain-derived neurotrophic factor (BDNF) in children with attention
 deficit-hyperactivity disorder (ADHD). Progress in NeuroPsychopharmacology and
 Biological Psychiatry. 2008; 32(8):1824–1828.
- 36. Sayyah, H. BDNF plasma level in ADHD children: correlation to different
 symptomatology. Curr Psychiatry [Egypt], 2009; 16, 284-294.
- 37. Sargin E, Akay AP, Resmi H, Cengizhan SA, Ozek H, Ellidokuz H, Miral S, Orcin
- E. Evaluation of Serum Brain-Derived Neurotrophic Factor Levels in Children with
 Attention Deficit Hyperactivity Disorder: Preliminary Data. Archives of
 Neuropsychiatry. 2012; 49(2): 96+.
- 38. Scassellati C, Zanardini R, Tiberti A, Pezzani M, Valenti V, Effedri P, Filippini E,
 Conte S, Ottolini A, Gennarelli M, Bocchio-Chiavetto L. Serum brain-derived
 neurotrophic factor (BDNF) levels in attention deficit-hyperactivity disorder
 (ADHD). European child & adolescent psychiatry. 2013; 23(3): 173-177.
- **39.** Liu L, Li H, Wang Y, Yang L, Qian Q, Wang Y. Association between GUC2C and ADHD:
- evidence from both categorical and quantitative traits. Psychiatry Research [Internet].
 2014 Dec 15 [cited 2023 Feb 12];220(1-2):708-10.

40. Sahin S, Yuce M, Alacam H, Karabekiroglu K, Say GN, Salıs O. Effect of
methylphenidate treatment on appetite and levels of leptin, ghrelin, adiponectin,
and brain-derived neurotrophic factor in children and adolescents with attention
deficit and hyperactivity disorder. International journal of psychiatry in clinical
practice. 2014; 18(4): 280–287.

- 41. Saadat F, Kosha M, Amiry A, Torabi G. Brain-Derived Neurotrophic Factor as a
 Biomarker in Children with Attention Deficit-Hyperactivity Disorder. Journal of
 Krishna Institute of Medical Sciences University. 2015; 4(4): 10-17.
- 42. Imşek Ş, Gençoğlan S, Yüksel T, Kaplan İ, Aktaş H, Alaca R. Evaluation of the
 Relationship between Brain-Derived Neurotrophic Factor Levels, and the Stroop
 Interference Effect in Children with Attention-Deficit Hyperactivity Disorder. Noro
 Psikiyatri Arsivi. 2016; 53(4): 348–352.
- 43. Bilgiç A, Toker A, Işık Ü, Kılınç İ. Serum brain-derived neurotrophic factor, glialderived neurotrophic factor, nerve growth factor, and neurotrophin-3 levels in
 children with attention-deficit/hyperactivity disorder. European child & adolescent
 psychiatry. 2017; 26(3): 355–363.
- 44. Reda M, El-Nady HG, Rabie MA, Fawzy R, Adel S, AwadAllah E, Moneim MA.
 Comparing brain-derived neurotrophic factor levels, intelligence, and memory in
 clinical subtypes of attention-deficit hyperactivity disorder. Middle East Current
 Psychiatry. 2016; 23(2): 56-62.
- 45. Cubero-Millán I, Ruiz-Ramos MJ, Molina-Carballo A, Martínez-Serrano S,
 Fernández-López L, Machado-Casas I, Tortosa-Pinto P, Ruiz-López A, LunaDelCastillo JD, Uberos J, Muñoz-Hoyos A. BDNF concentrations and daily fluctuations
 differ among ADHD children and respond differently to methylphenidate with no
 relationship with depressive symptomatology. Psychopharmacology. 2016;
 234(2): 267–279
- 46. Taha H, Elsheshtawy E, Mohamed SI, Al-Azazzy O, Elsayed M, Ibrahim SAS.
 Correlates of brain derived neurotrophic factor in children with attention deficit

hyperactivity disorder: A case-control study. Egyptian Journal of Psychiatry. 2017;
38(3): 159-163.

- 47. Wang LJ, Wu CC, Lee MJ, Chou MC, Lee SY, Chou WJ. Peripheral Brain Derived
 Neurotrophic Factor and Contactin-1 Levels in Patients with Attention
 Deficit/Hyperactivity Disorder. Journal of clinical medicine. 2019; 8(9):1366.
- 48. Yurteri N, Şahin İE, Tufan AE. Altered serum levels of vascular endothelial growth
 factor and glial-derived neurotrophic factor but not fibroblast growth factor2 in
 treatment-naive children with attention deficit/hyperactivity disorder. Nordic journal
 of psychiatry. 2019; 73(4-5): 302–307.
- 49. El Ghamry R, El-Sheikh M, Meguid MA, Nagib S, El Gabry DA. Plasma brain
 derived neurotrophic factor (BDNF) in Egyptian children with attention deficit
 hyperactivity disorder. Middle East Current Psychiatry. 2021; 28: 22.
- 50. Gumus C, Yazici IP, Yazici KU, Ustundag B. Increased Serum Brain-derived
 Neurotrophic Factor, Nerve Growth Factor, Glial-derived Neurotrophic Factor and
 Galanin Levels in Children with Attention Deficit Hyperactivity Disorder, and the
 Effect of 10 Weeks Methylphenidate Treatment. Clinical psychopharmacology and
 neuroscience: the official scientific journal of the Korean College of
 Neuropsychopharmacology. 2022; 20(4): 635–648.
- 51. Akay AP, Resmi H, Güney SA, Erkuran HÖ, Özyurt G, Sargin E, et al. Serum brainderived neurotrophic factor levels in treatment-naïve boys with attentiondeficit/hyperactivity disorder treated with methylphenidate: an 8-week,
 observational pretest–posttest study. European Child & Adolescent Psychiatry.
 2017 Jul 14;27(1):127–35.

52. Amiri A, Torabi Parizi G, Kousha M, Saadat F, Modabbernia MJ, Najafi K, Atrkar
Roushan Z. Changes in plasma Brain-derived neurotrophic factor (BDNF) levels
induced by methylphenidate in children with Attention deficit-hyperactivity disorder
(ADHD). Progress in Neuro-Psychopharmacology and Biological Psychiatry. 2013;
47: 20-24.

- 53. Caye A, Kieling RR, Rocha TB, Graeff-Martins AS, Geyer C, Krieger F, et al.
 Schedule for Affective Disorders and Schizophrenia for School-Age Children –
 Present and Lifetime Version (K-SADS-PL), DSM-5 update: translation into
 Brazilian Portuguese. Brazilian Journal of Psychiatry. 2017 Dec;39(4):384–6.
- 54. Mattos P, Serra-Pinheiro MA, Rohde LA, Pinto D. A Brazilian version of the MTASNAP-IV for evaluation of symptoms of attention-deficit/hyperactivity disorder and
 oppositional-defiant disorder. Revista de psiquiatria do Rio Grande do Sul.
 2006;28(3):290-7.

55. Benczik E. Escala de avaliação dos comportamentos infantojuvenis no TDAH em ambiente familiar - Versão para pais (ETDAH-PAIS). 1st ed. Vol. 1. Memnon; 2018.

- 56. Benczik E. Escala de Autoavaliação do TDAH-Versão para crianças e
 adolescentes (ETDAH-Criad). 1st ed. Vol. 1. Memnon; 2018.
- 57. Kamakura W, Mazzon JA. Socioeconomic Stratification Criteria and Classification
 Tools in Brazil. Revista de administração de empresas. 2016; 56:55-70.
- 58. Associação Brasileira de Empresas de Pesquisa (ABEP). Alterações na aplicação
- do Critério Brasil, válidas a partir de 16/04/2018. 2018.

- 59. Fernandes C. Validação do questionário de avaliação de atividade física em
 crianças com idade entre 9 e 10 anos. Vitória. Tese [Mestrado em Educação
 Física] Universidade Federal do Espírito Santo; 2012.
- 830 60. Ministério do Desenvolvimento e Combate à fome Secretaria de Avaliação e
- 831 Gestão da Informação (MDS-SAGI). Escala brasileira de Insegurança Alimentar
- (EBIA): análise psicométrica de uma dimensão da Segurança Alimentar e
 Nutricional. Estudo técnico nº1/2014.
- 61. Ministério da Saúde. Orientações para avaliação de marcadores de consumo
 alimentar na atenção básica. 2015, access on feb 11 of 2023]. Avaiable on
 https://bvsms.saude.gov.br/bvs/publicacoes/marcadores consumo alimentar at
- 837 <u>encao basica.pdf</u>
- 62. Gibson RS, Ferguson EL. An interactive 24-hour recall for assessing the adequacy
 of iron and zinc intakes in developing countries. Washington, DC, and California:
 International Food Policy Research Institute (IFPRI) and International Center for
- Tropical Agriculture (CIAT). 2008.
- 63. Gibson RS, Charrondiere UR, Bell W. Measurement errors in dietary assessment
 using self-reported 24-hour recalls in low-income countries and strategies for their
 prevention. Advances in Nutrition. 2017;8(6):980-991.
- 64. Kidscape: preventing bullying, protecting children. [Accessed on feb 11 of 2013].
 Available on http://www.kidscape.org.uk/ Access on: 11/02/2023.
- 65. Delgado AB, Lima ML. Contribution to Concurrent Validity of Treatment
 Adherence. Psicologia, Saúde e Doenças. 2001;2(2):81-100.

66. Pereira BA de AX, Schram PFC, Azevedo RCS de. Evaluation of the Brazilian
 version of the CRAFFT/CESARE scale for screening drug use by adolescents.

851 Ciência & Saúde Coletiva. 2016 Jan;21(1):91–9.

- 67. Silveira DX, Jorge MR. Psychometric properties of the epidemiologic screening
 scale for depression (CES-D) in clinical and non-clinical populations of adolescents
- and young adults. Revista de psiquiatria clínica (São Paulo); 1998; 25(5):251-61.
- 68. Biaggio AMB, Natalício L, Spielberger CD. Desenvolvimento da forma
 experimental em português do Inventário de Ansiedade Traço-Estado (IDATE).
 Rio de Janeiro. Arguivos brasileiros de psicologia. 1977; 29 (3): 3144.
- 69. Leite WB. Avaliação das propriedades psicométricas da escala de autorrelato de
 sintomas do transtorno do déficit de atenção e hiperatividade ASRS-18. Belo
 Horizonte. Tese [Mestrado em Neurociências] Universidade Federal de Minas
 Gerais. 2011.
- 70. Mendéz, EB. Uma versão brasileira do AUDIT (Alcohol use disorders identification
 test). Pelotas. Tese [Mestrado em Epidemiologia] Universidade Federal de
 Pelotas. 1999.
- 71. Costa DS, Paula JJ de, Malloy-Diniz LF, Romano-Silva MA, Miranda DM. Parent
 SNAP-IV rating of attention-deficit/hyperactivity disorder: accuracy in a clinical
 sample of ADHD, validity, and reliability in a Brazilian sample. Jornal de Pediatria.
 2019 Nov;95(6):736–43.
- 72. Ferreira V. Escala de distúrbios do sono em crianças: tradução, adaptação cultural
 e validação. São Paulo.Tese [Mestrado em Ciências] Universidade Federal de
 São Paulo Escola Paulista de Medicina. 2009.

872	73. Cianchetti C, Pasculli M, Pittau A, Campus MG, Carta V, Littarru R, et al. Child and
873	Adolescent Behavior Inventory (CABI): Standardization for age 6-17 Years and
874	First Clinical Application. Clinical Practice & Epidemiology in Mental Health. 2017
875	Mar 22;13(1):20–6.
876	74. Oliveira TD, Costa DS de, Albuquerque MR, Malloy-Diniz LF, Miranda DM, de
877	Paula JJ. Cross-cultural adaptation, validity, and reliability of the Parenting Styles
878	and Dimensions Questionnaire – Short Version (PSDQ) for use in Brazil. Revista
879	Brasileira de Psiquiatria. 2018 Jun 11;40(4):410–9.
880	75. Bartholomeu D, Silva MCR da, Montiel JM. Teste de habilidades sociais para

- crianças e adolescentes em situação escolar (THAS-C).1st ed. Vol. 1. Memnon;
 2014.
- 76. Pasquali L. Manual Técnico e de Aplicação do Teste Não-Verbal de Raciocínio
 para Crianças TNVRI. 1st ed. Vol. 1. São Paulo SP. Vetor editora; 2005. P.1885
 82.
- 77. Rueda FJM. BPA Bateria psicológica para avaliação da atenção. 1st ed. Vol. 1.
 São Paulo SP. Vetor editora; 2013.
- 78. Rueda FJM, Monteiro RM de. Psychological Battery for Attention Assessment
 (BPA): performance of different age groups. Psico-USF. 2013;18(1):99–108.
- 79. Sedó M, Paula JJ de, Malloy-Diniz LF. Five Digit Test. 1st ed. Vol. 1. Hogrefe;
 2015.
- 80. Salles JF de, Fonseca RP, Rodrigues CC, Mello CB, Barbosa T, Miranda MC.
 Development of the Child Brief Neuropsychological Assessment Battery
 NEUPSILIN-INF. Psico-USF. 2011; 16(3): 297-305.

- 895 81. Crispim SP et al. Manual fotográfico de quantificação alimentar. 2017. Curitiba:
 896 Universidade Federal do Paraná. 2017.
- 897 82. International Dietary Data Expansion Project. 24-hour Dietary Recall (24HR).
- 898 [Accessed on feb 11 of 2023]. Available on
- 899 https://inddex.nutrition.tufts.edu/data4diets/data-source/24-hour-dietary-recall-
- 900 <u>24hr</u>
- 83. Guy W. Clinical Global Impression (CGI): ECDEU Assessment Manual for
 Psychopharmacology. Department of Health, Education, and Welfare. 1976.
- 84. Busner J, Targum SD. The Clinical Global Impressions Scale: applying a research
 tool in clinical practice. Psychiatry (edgmont). 2007;4(7): 29-37.
- 85. Lima MS de et al. The Portuguese version of the Clinical Global Impression –
 Schizophrenia Scale: validation study. Revista Brasileira de Psiquiatria.
 2007;29(3):246-9

86. Advokat C, Scheithauer M. Attention-deficit hyperactivity disorder (ADHD) stimulant medications as cognitive enhancers. Frontiers in Neuroscience. 2013;7(82).

- 87. Storebø OJ, Ramstad E, Krogh HB, Nilausen TD, Skoog M, Holmskov M, et al.
 Methylphenidate for children and adolescents with attention deficit hyperactivity
 disorder (ADHD). Cochrane Database of Systematic Reviews. 2015 Nov 25.
- 88. Cortese S, Adamo N, Del Giovane C, Mohr-Jensen C, Hayes AJ, Carucci S, et al.
 Comparative efficacy, and tolerability of medications for attention-deficit
 hyperactivity disorder in children, adolescents, and adults: a systematic review and
- 917 network meta-analysis. Lancet Psychiatry. 2018 Sep;5(9):727-738.

- 89. Lin SK, Tsai SM, Huang JC, Lee SC, Wu SH, Wu SH, et al. Effects of storage time
 and temperature on the stability of glutathione in deproteinized blood samples.
 Journal of Food and Drug Analysis. 2020 Jul 14;14(2).
- 90. Gejl AK, Enevold C, Bugge A, Andersen MS, Nielsen CH, Andersen LB.
 Associations between serum and plasma brain-derived neurotrophic factor and
 influence of storage time and centrifugation strategy. Scientific Reports. 2019; 9:
 924 9655.
- 925 91. de Jager W, Bourcier K, Rijkers GT, Prakken BJ, Seyfert-Margolis V. Prerequisites
- 926 for cytokine measurements in clinical trials with multiplex immunoassays. BMC 927 Immunology. 2009;10(1):52.
- 928 92. Aziz N, Detels R, Quint JJ, Li Q, Gjertson D, Butch AW. Stability of cytokines,
 929 chemokines and soluble activation markers in unprocessed blood stored under
 930 different conditions. Cytokine. 2016 Aug; 84:17–24.
- 93. Gong Y, Liang S, Zeng L, Ni Y, Zhou S, Yuan X. Effects of blood sample handling
- 932 procedures on measurable interleukin 6 in plasma and serum. Journal of Clinical933 Laboratory Analysis. 2019 May 26;33(7).
- 934 94. Chiswick EL, Duffy E, Japp B, Remick D. Detection and Quantification of Cytokines
 935 and Other Biomarkers. Methods in Molecular Biology [Internet]. 2011 Dec 21; 844:15–
 936 30.
- 937 95. Jansen EHJM, Beekhof PK, Cremers JWJM, Viezeliene D, Muzakova V, Skalicky
 938 J. Short-Term Stability of Biomarkers of Oxidative Stress and Antioxidant Status in
 939 Human Serum. ISRN Biomarkers. 2013 Jun 18; 2013:1–5.

940	96. Jansen EHJM, Beekhof PK, Viezeliene D, Muzakova V, Skalicky J. Long-term
941	stability of oxidative stress biomarkers in human serum. Free Radical Research.
942	2017 Nov 28;51(11-12):970–7.
040	07 Octorborg L. Disselve T. Adherence to Mediaction. The New England Journal of

- 943 97. Osterberg L, Blaschke T. Adherence to Medication. The New England Journal of
 944 Medicine. 2005; 353:487-97.
- 945 98.Cortese S et al. Candidate diagnostic biomarkers for neurodevelopmental
 946 disorders in children and adolescents: a systematic review. World Psychiatry.
 947 2023; 22(1): 129-149.

948

949 Supporting Information

950 S1_File. SPIRIT Checklist.

Fig 1. Schedule of enrolment, interventions, and assessments.

		STUDY PERIOD								
		Enrolment Allocation Post-allocation Close- out								
	TIMEPOINT**	-t,	t,	t₁ baseline	t2 4 sem	t3 8 sem	t ₄ 12 sem	t 5 18 sem	t ₅ 24 sem	
		EN	ROLMENT:							
	Eligibility screen	х								
medRxiv p <mark>(which v</mark>	reprint doi: https://doi.org/10.1101/2023.03.03.23286780; this version vas not certified by peer review) is the author/funder, who has gran It is made available under a DSBM 2.0	posted March 5, 2023 ted medRxiv a license nternational license .	The copyright holder f to display the preprint i	or this preprint n perpetuity.						
	K-Sads-PL	х								
	Sociodemographic data	х								
	Allocation		х							
		INTER	RVENTIONS	:						
		Child G	uestionnair	es						
	ADHD Self-Assessment Scale – Version for Children and Adolescents (ETDAH-Cri Ad)			х			х		х	
	ADHD Behavior Assessment Scale - Parental Version (ETDAH-parents)			х			х		х	
	SNAP-IV			х			х		х	
	Psychiatry interview (standard record)			х	х	х	х	х	х	
	Physical Examination			х	х	х	х	х	х	
	Measure Treatment Adherence (MTA) and pill count			х	x	х	х	х	х	
	24-hour food recall			х			х		х	
	SISVAN food consumption markers			х			х		х	
	Bullying questionnaire (Kidscape)			х			х		х	
	Physical activity questionnaire			х			х		х	

	Scale of sleep disorders in children			х			х		х		
	Social Skills Test for Children and Adolescents in School Situation (THAS-C)			х			х		х		
	CRAFFT/CESARE (scale for screening drug use)			х			х		х		
	CABI (Behavior Inventory for Children and Adolescents)			х			х		х		
	Caregivers Questionnaires										
	Parenting Styles and Dimensions Questionnaire – Short Version (PSDQ)			х			х		х		
medRxiv p <mark>(which v</mark>	eprint doi: https://doi.org/10.1101/2023.03.03.23286780: this version as for a or li city peocyte C Store available under a CC-BY 4.0 It is made available under a CC-BY 4.0	posted March 5, 2023. Ited medRxiv a license International license .	The copyright holder f to display the preprint i	or this preprint n perpetuity.			х		х		
	Epidemiological Studies Center Depression Scale (CES-D)			х			х		х		
	State-Trait Anxiety Inventory (IDATE)			х			х		х		
	Audit (Alcohol Use Disorder Identification Test)			х			х		х		
	Asr18 (Adult Self-Report Scale)			х			х		х		
	Ν	leuropsycho	logical Ass	essment							
	TNVRI			х			х		х		
	BPA			х			х		х		
	FDT			х			х		х		
	Neupsilin			х							
		Pharmacolo	ogical Interv	ention							
	Methylphenidate (short acting)			х	х	х	х	х	х		
		San	nple Blood								
	BDNF			х			х		х		
	Cytokines			x			х		х		
	Oxidative stress			x			х		х		
		100	ESSMENTS.								
ASSESSMENTS:											

First trial assessment		х			
Second trial assessment				х	
Third trial assessment					х

Fig. 2. The participants visit.



* Assessment points (Psychiatric clinical follow-up, Nutrition assessment, Neuropsychological assessment, Sample Blood, Questionnaires and Scales)

** Methylphenidate prescription after first blood sample.

***Children who finished the trial times will be transferred to the general outpatient

clinic of child psychiatry at the UFV medical school.

Figure 2